The Regeneron Genetics Center is a wholly-owned subsidiary of the Company organized to collaborate with health systems and research groups to elucidate, on a large scale, genetic factors that cause or influence a range of human diseases. Building upon Regeneron's strengths in mouse genetics and genetics-driven drug discovery and development, the Center will specialize in ultra-high-throughput exome sequencing and computational biology; discovery of genotype-phenotype associations through linkage to well-annotated de-identified patient electronic medical records; and validation of discoveries using Regeneron's VelociGene technology. Our interests encompass a breadth of different areas such as Mendelian and family frameworks, large-scale population genetics (both common and rare variants), and gene-gene interactions. Program goals include target discovery, indication discovery, and patient-disease stratification. Objectives include advancing basic science around the world through public sharing of discoveries, providing clinically-valuable insights to physicians and patients of collaborating health-care systems, and identifying novel targets for drug development.